Skip to main content

Table 3 Geometric mean and 95% confidence interval for sex hormone concentrations, separately for placebo and active randomization groups for breast cancer cases and controls from the Women’s Health Initiative CEE trial

From: Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects

  CEE trial
  Placebo Active treatment
  Cases Controls P-value* Cases Controls P-value*
Estradiol (pg/ml)       
Baseline 12.36 (5.59, 27.38) 10.56 (4.36, 25.57) 0.01 12.72 (3.88, 41.67) 10.43 (4.30, 25.32) 0.01
Year 1 10.31 (3.55, 29.94) 9.37 (3.64, 24.14) 0.21 26.47 (7.89, 88.76) 23.96 (6.77, 84.84) 0.27
Bioavailable estradiol (pg/ml)       
Baseline 8.53 (3.41, 21.33) 6.76 (2.59, 17.65) 0.001 8.74 (2.53, 30.20) 6.54 (2.27, 18.84) 0.001
Year 1 6.99 (2.29, 21.28) 6.05 (2.21, 16.57) 0.08 12.33 (3.66, 41.57) 10.21 (3.26, 32.02) 0.03
Estrone (pg/ml)       
Baseline 41.05 (17.54, 96.08) 36.23 (15.48, 84.79) 0.05 41.25 (16.66, 102.15) 36.44 (15.66, 84.80) 0.05
Year 1 38.54 (14.68, 101.17) 33.70 (12.06, 94.13) 0.08 124.39 (31.09, 497.59) 134.65 (30.72, 590.11) 0.44
Estrone sulfate (ng/ml)       
Baseline 0.86 (0.41, 1.81) 0.77 (0.33, 1.79) 0.07 0.80 (0.29, 2.20) 0.77 (0.35, 1.69) 0.59
Year 1 0.76 (0.51, 1.49) 0.62 (0.43, 1.49) 0.001 1.68 (0.65, 6.84) 1.70 (0.69, 7.06) 0.94
SHBG (Nmol/L)       
Baseline 34.11 (14.47, 80.39) 39.99 (15.30, 104.52) 0.02 34.05 (13.11, 88.43) 42.79 (15.19, 120.50) 0.002
Year 1 34.54 (15.30, 77.95) 40.86 (15.73, 106.12) 0.01 82.34 (24.57, 276.00) 99.61 (28.47, 348.54) 0.03
  1. Samples are excluded if changes from baseline to year 1 log-transformed concentrations are outside the interquartile range by twice its width.
  2. *P-value from Student’s t-test comparison of case versus control values. CEE, conjugated equine estrogens; SHBG, sex hormone binding globulin.